Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Janssen’s Diabetes Drug Shows Promise Despite Serious Side Effects

By Ryan Bushey | June 15, 2016

Janssen, a subsidiary of Johnson & Johnson (J&J), announced some intriguing new data regarding its diabetes drug Invokana (canagliflozin).

Results from a randomized, Phase 2 study featuring 351 patients with inadequately controlled type 1 diabetes mellitus demonstrated Invokana was able to simultaneously lower mean glucose levels and glycemic variability, according to FiercePharma.

Furthermore, the drug increased the amount of time study participants spent within targeted glucose ranges. Janssen’s release noted there were “no meaningful changes in the time patients spent below target” in the different test groups.

The treatment was generally well-tolerated, but there was an increased risk of ketoacidosis, which is a condition that causes the body to overproduce excess blood acids due to a lack of insulin in the body.

The U.S. Food and Drug Administration on Tuesday updated its drug label warnings about the risk for acute kidney injury that can occur when taking the type 2 diabetes drugs, Invokana and AstraZeneca’s Farxiga. Acute kidney injury is a complication of diabetic ketoacidosis.

Overall, this study data indicates it could add another indication to a blockbuster for J&J since it is only approved for type 2 diabetes as of right now. The pharmaceutical giant made $325 million in worldwide sales from this drug in the first quarter of 2016, added FiercePharma.

Janssen announced this study data on Monday at the annual meeting of the American Diabetes Association.

Read more coverage from the meeting below.

IBM to Develop New Digital Tools for Diabetes Research

Sanofi’s Diabetes Drug Hits Phase 3 Study Targets

Novo Diabetes Drug Cuts Heart Risks by Less-Than-Hoped 13 Percentage


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE